INTERCEPT PHARMACEUTICALS, INC. Insider Trading for April 2014
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INTERCEPT PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in INTERCEPT PHARMACEUTICALS, INC. for April 2014.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 18 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | M | 0.00 | 324 | 0 | 649 | |
| Apr 18 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | M | 0.00 | 324 | 0 | 2,267 | 1.9 K to 2.3 K (+16.68 %) |
| Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 10,000 | 86,667 | 216,628 | |
| Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 2,866 | 24,839 | 42,999 | |
| Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 14,332 | 124,211 | 226,628 | |
| Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 2.89 | 13,111 | 37,876 | 0 | |
| Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 242.22 | 10,000 | 2,422,166 | 470,174 | 480.2 K to 470.2 K (-2.08 %) |
| Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 10,000 | 86,667 | 480,174 | 470.2 K to 480.2 K (+2.13 %) |
| Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 2,866 | 24,839 | 470,174 | 467.3 K to 470.2 K (+0.61 %) |
| Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 14,332 | 124,211 | 467,308 | 453 K to 467.3 K (+3.16 %) |
| Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 2.89 | 13,111 | 37,876 | 452,976 | 439.9 K to 453 K (+2.98 %) |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Option Exercise | A | 266.01 | 6,421 | 1,708,050 | 6,421 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Option Exercise | A | 266.01 | 1,720 | 457,537 | 1,720 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Grant | A | 0.00 | 1,410 | 0 | 1,410 | 0 to 1.4 K |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | A | 266.01 | 22,931 | 6,099,875 | 22,931 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | A | 266.01 | 5,733 | 1,525,035 | 5,733 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Grant | A | 0.00 | 4,699 | 0 | 439,865 | 435.2 K to 439.9 K (+1.08 %) |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 21.50 | 1,154 | 24,811 | 8,365 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | A | 266.01 | 6,650 | 1,768,967 | 6,650 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | A | 266.01 | 1,835 | 488,128 | 1,835 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 279.00 | 1,154 | 321,966 | 13,510 | 14.7 K to 13.5 K (-7.87 %) |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 21.50 | 1,154 | 24,811 | 14,664 | 13.5 K to 14.7 K (+8.54 %) |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Grant | A | 0.00 | 1,504 | 0 | 13,510 | 12 K to 13.5 K (+12.53 %) |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | A | 266.01 | 8,255 | 2,195,913 | 8,255 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | A | 266.01 | 1,835 | 488,128 | 1,835 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Grant | A | 0.00 | 1,504 | 0 | 15,183 | 13.7 K to 15.2 K (+10.99 %) |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | A | 266.01 | 2,293 | 609,961 | 2,293 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | A | 266.01 | 516 | 137,261 | 516 | |
| Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Grant | A | 0.00 | 423 | 0 | 7,464 | 7 K to 7.5 K (+6.01 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | Micheli Francesco | 10% Owner | Option Exercise | X | 10.40 | 865,381 | 8,999,962 | 0 | |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | Micheli Francesco | 10% Owner | Sell | S | 293.91 | 30,623 | 9,000,406 | 6,454,953 | 6.5 M to 6.5 M (-0.47 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | Micheli Francesco | 10% Owner | Buy | X | 10.40 | 865,381 | 8,999,962 | 6,485,576 | 5.6 M to 6.5 M (+15.40 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | Micheli Francesco | 10% Owner | Sell | S | 320.00 | 318,695 | 101,982,400 | 5,620,195 | 5.9 M to 5.6 M (-5.37 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | 10% Owner | Option Exercise | X | 10.40 | 865,381 | 8,999,962 | 0 | |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | 10% Owner | Sell | S | 293.91 | 30,623 | 9,000,406 | 6,454,953 | 6.5 M to 6.5 M (-0.47 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | 10% Owner | Buy | X | 10.40 | 865,381 | 8,999,962 | 6,485,576 | 5.6 M to 6.5 M (+15.40 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | 10% Owner | Sell | S | 320.00 | 318,695 | 101,982,400 | 5,620,195 | 5.9 M to 5.6 M (-5.37 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 320.00 | 81,305 | 26,017,600 | 1,653,629 | 1.7 M to 1.7 M (-4.69 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Option Exercise | X | 10.40 | 865,381 | 8,999,962 | 0 | |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Sell | S | 293.91 | 30,623 | 9,000,406 | 6,454,953 | 6.5 M to 6.5 M (-0.47 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Buy | X | 10.40 | 865,381 | 8,999,962 | 6,485,576 | 5.6 M to 6.5 M (+15.40 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | TALLARIGO LORENZO | Director | Sell | S | 320.00 | 318,695 | 101,982,400 | 5,620,195 | 5.9 M to 5.6 M (-5.37 %) |
| Apr 11 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 320.00 | 81,305 | 26,017,600 | 1,654,603 | 1.7 M to 1.7 M (-4.68 %) |
| Apr 09 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 10.40 | 2,000 | 20,800 | 2,000 | |
| Apr 09 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 286.30 | 1,000 | 286,300 | 7,041 | 8 K to 7 K (-12.44 %) |
| Apr 09 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 283.00 | 500 | 141,500 | 8,041 | 8.5 K to 8 K (-5.85 %) |
| Apr 09 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 280.00 | 500 | 140,000 | 8,541 | 9 K to 8.5 K (-5.53 %) |
| Apr 09 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 10.40 | 2,000 | 20,800 | 9,041 | 7 K to 9 K (+28.41 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Option Exercise | M | 0.00 | 4,868 | 0 | 34,074 | |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President and CEO | Buy | M | 0.00 | 4,868 | 0 | 435,166 | 430.3 K to 435.2 K (+1.13 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 0.00 | 649 | 0 | 4,543 | |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 0.00 | 649 | 0 | 7,041 | 6.4 K to 7 K (+10.15 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 4,326 | 44,991 | 0 | |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 0.00 | 1,622 | 0 | 11,358 | |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 321.95 | 879 | 282,997 | 13,679 | 14.6 K to 13.7 K (-6.04 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 338.16 | 500 | 169,082 | 14,558 | 15.1 K to 14.6 K (-3.32 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 335.84 | 1,000 | 335,844 | 15,058 | 16.1 K to 15.1 K (-6.23 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 334.52 | 388 | 129,793 | 16,058 | 16.4 K to 16.1 K (-2.36 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 333.22 | 1,626 | 541,809 | 16,446 | 18.1 K to 16.4 K (-9.00 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 330.06 | 1,000 | 330,060 | 18,072 | 19.1 K to 18.1 K (-5.24 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 4,326 | 44,991 | 19,072 | 14.7 K to 19.1 K (+29.34 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 0.00 | 1,622 | 0 | 14,746 | 13.1 K to 14.7 K (+12.36 %) |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 0.00 | 1,298 | 0 | 9,087 | |
| Apr 03 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 0.00 | 1,298 | 0 | 12,006 | 10.7 K to 12 K (+12.12 %) |